{"schema_version":"secwatch.filing_event.v1","accession":"0001522767-25-000010","form_type":"8-K","ticker":"MRMD","cik":"0001522767","company_name":"MARIMED INC.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.878819+00:00","generated_at":"2026-05-25T10:06:02.586121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MariMed reports record FY2024 revenue $158M; Q4 margins compress, adjusted EBITDA up in Q4","bullets":["Q4 2024 revenue $39.0M (vs $38.9M); full-year revenue $158.0M (+6.3% YoY).","GAAP gross margin fell to 33% in Q4 from 45% YoY; full-year margin 40% vs 44%.","Full-year GAAP net loss improved to $12.1M from $16.0M; adjusted EBITDA $19.6M vs $24.7M.","Wholesale revenue up 29% annually; Betty's Eddies top-selling edible in MA and MD.","CEO cites 10 revenue-generating assets added over past two years for 2025 growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001522767-25-000010","json":"https://secwatch.observer/filing/0001522767-25-000010.json","markdown":"https://secwatch.observer/filing/0001522767-25-000010.md","text":"https://secwatch.observer/filing/0001522767-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1522767/000152276725000010/0001522767-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1522767/000152276725000010/mrmd-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T10:06:02.586121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}